Funding to support scale-up and market expansion of plant-based nutraceutical brand
Kotak Alternate Asset Managers Limited (Kotak Alts), through its Kotak Life Sciences Fund I (KLSF-I), has invested INR 400 Mn in Zeroharm Sciences. The fund focuses on early to growth stage life sciences and healthcare businesses.
The investment provides capital to support Zeroharm’s scale-up plans, brand visibility, customer engagement and expansion into new markets.
Ashish Ranjan, Director at Kotak Alts, said, “The Indian nutraceuticals market is supported by favourable macroeconomic, demand, and supply side drivers. It remains in the early stages of adoption and is poised for exponential growth. Zeroharm is redefining preventive care and wellness by seamlessly integrating the timeless wisdom of Ayurveda with advanced technology, delivering solutions that are safe, effective, and scalable.”
Founded in 2020 by Sachin Darbarwar, Zeroharm is a plant-based nutraceutical direct-to-consumer brand with in-house capabilities across extraction, formulation R&D and manufacturing. The company sells its products through its website, e-commerce platforms and quick commerce players in India. It is also expanding its presence in the USA, UK and the Middle East.
Sachin Darbarwar, Co-Founder and CEO of Zeroharm Sciences, said, “This investment represents an important milestone in Zeroharm’s evolution as we transition from a strong product market foundation to the next phase of scaled growth. The partnership with Kotak Alts and Alkemi Growth Capital brings not only growth capital but also long term partners with a deep understanding of the healthcare and life sciences ecosystem. Kotak Alts’ conviction in our fully integrated model—encompassing extraction, formulation, R&D, and manufacturing—strongly reinforces our vision of building a science led, trusted nutraceuticals brand from India for global markets.”
